Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma

NCT01870726 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01870726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01870726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
January 9, 2014
Completion date
December 23, 2016
Enrollment
43 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

c-met inhibitor; pi3k inhibitor, pten mutations, homozygous del. of pten or pten neg. by ihc, c-met ampli. by fish, inc280, bkm120, buparlisib; recurrent gbm